Table 1.

Characteristics of 47 patients who underwent allogeneic stem-cell transplantation for cutaneous T-cell lymphoma

Characteristic	No. of patients (%)
Median age at transplant, years (range)	51.5 years (19–72)
Sex
Male	20 (43)
Female	27 (57)
Ethnicity
Caucasian	33 (69)
African American	11 (23)
Hispanic	4 (8)
Median no. of prior chemotherapy regimens (range)	6 (2–11)
Time from diagnosis to transplant, median (range)	2.25 years (126 days–22 years)
Mycosis fungoides	1.3 years (258 days–22 years)
Mycosis fungoides with LCT	3.77 years (283 days–11.3 years)
Mycosis fungoides with SS	2.2 years (126 days–6.31 years)
Mycosis fungoides with SS and LCT	2.45 years (376 days–9.3 years)
Response to pretransplant therapy (%)
CR/CRu	7 (15)
PR	28 (60)
SD/PD	12 (26)
Median pruritus score (range)
At diagnosis (n = 44)	8 (1–10)
Before transplant (n = 25)	3 (0–8)
One year after transplant (n = 22)	0 (0–8)
Stem cell source
HPC-A	35 (74)
HPC-M	12 (26)
Donor type
Matched sibling	21 (45)
Matched unrelated	24 (51)
One antigen mismatched related	2 (4)
Median CD34+ cell dose (106 cells/kg)	5.3 (0.99–33.56)
Recipient → donor
Male → male	14
Male → female	6
Female → female	6
Female → male	21
Conditioning regimen
Fludarabine/melphalan ± thymoglobulin	42 (89)
Fludarabine/busulfan	3 (6)
Fludarabine/cyclophosphamide ± rituximab	2 (4)
Graft-versus-host-disease prophylaxis (%)
Tacrolimus/methotrexate	47 (100)
Total body skin electron beam radiation (%)	42 (89)

All data are the number of patients (%) unless otherwise noted.

CR, complete remission; CRu, complete remission unconfirmed; PR, partial remission; SD, stable disease; PD, progressive disease; HPC-A, hematopoietic progenitor cells-apheresis; HPC-M, hematopoietic progenitor cells-marrow; LCT, large-cell transformation; SS, Sézary syndrome.